Loading...
•
Dec 31, 2024
•/
Pharvaris Q4 2024 Earnings Report
Pharvaris reported a net loss in Q4 2024 as it continued advancing its clinical programs, with no reported revenue and increased R&D expenses.
Key Takeaways
Pharvaris ended Q4 2024 with a net loss of €34.8M and zero revenue, reflecting ongoing investment in clinical trials. The company maintained a strong liquidity position with €281M in cash and cash equivalents.
Reported net loss of €34.8M with EPS of -€0.64
Revenue remained at €0 as the company continues in clinical stages
R&D expenses increased significantly to support late-stage trials
Cash position remained strong at €281M at quarter-end
Pharvaris
Pharvaris
Forward Guidance
Pharvaris expects continued progress in its Phase 3 clinical programs with topline data for CHAPTER-3 anticipated in the second half of 2026.
Positive Outlook
- Target enrollment completed for RAPIDe-3 Phase 3 trial
- Enrollment underway for CHAPTER-3 Phase 3 prophylaxis trial
- Strong cash position supports ongoing development
- Orphan drug designation granted by European Commission
- Long-term data reinforces clinical potential of deucrictibant
Challenges Ahead
- No revenue generation as development-stage company
- Net losses expected to continue due to high R&D spend
- Regulatory approvals still pending
- Dependence on successful trial outcomes
- Market launch timelines extend into future years